ZS Analysis: $29B Raised

Transform patient technology for scalable impact; Modernize go-to-market strategies with AI; Enhance commercial effectiveness in life sciences; Improve customer experience through data-driven insights; Optimize supply chain design and planning.

Recognized as a leader in AI and analytics by Everest Group; Partners with major healthcare organizations; Committed to environmental, social, and governance initiatives.

In the last two years, ZS Associates has made the following acquisitions:

1. Digital Additive - Acquired approximately 9 months ago, Digital Additive is a Salesforce digital marketing agency based in Atlanta.
2. Trials.ai - Acquired approximately 25 months ago, Trials.ai is a healthcare-focused AI and analytics firm aimed at enhancing clinical trials.

ZS Associates has received notable recognition from the CDC for their novel approach to AI and data analytics in healthcare. Additionally, two employees from ZS were honored with Built In's 2023 Moxie Award, highlighting the company's commitment to excellence in technology and innovation.

ZS Associates predicts that by 2025, there will be a significant increase in investments in data, digital, and AI across various business domains, with 93% of leaders anticipating this trend. They emphasize that technology, data, and AI will drive innovation in the pharmaceutical industry, while also highlighting the importance of talent in leveraging these advancements. The company aims to equip leaders with insights and action plans to fully realize the potential of data and AI in healthcare and life sciences.